Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
Alzheimer’s Association calls for federal involvement to increase dementia care workforce, training...
By
Lois A. Bowers
Jan 29, 2024
“Congress should consider the steps it can take at the federal level, including expanding the necessary workforce and improving dementia training standards and access,” as part of efforts to “help...
Focus on briefs: Dementia
Feb 01, 2023
Alzheimer’s blood test, Aducanumab approval issues, Medicare coverage of brain scans that diagnose dementia, Some at higher risk for Alzheimer’s
New breakthroughs: Precision medicine for Alzheimer’s
By
Vik Chandra
Aug 08, 2019
For senior living communities already offering quality dementia services, working in concert with providers offering precision medicine solutions could be the next step in the evolution of state-of-the-art...
Allopurinol may cut risk for neurodegenerative diseases
May 19, 2023
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
As more seniors turn to music therapy, health insurer says it will help payers find their groove
By
Aaron Dorman
Nov 02, 2023
Longevity Health will now provide coverage for a platform that provides music therapy via singing to senior living communities.
Medicare spending spikes for dementia diagnoses in seniors
Jun 13, 2022
Medicare spending was higher for adults with a formal clinical diagnosis of dementia versus a positive screening for cognitive impairment.
Does cancer protect against Alzheimer’s?
By
Lois A. Bowers
May 09, 2016
New research explores whether what causes cancer in some people may protect them from developing Alzheimer’s disease.
Alzheimer’s misdiagnoses running up big Medicare bills
By
Emily Mongan
Jul 28, 2015
Medicare beneficiaries who receive a misdiagnosis of Alzheimer’s could amass between $9,500 and $14,000 in additional medical costs each year until they are correctly diagnosed, according to a new...
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...